Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by priceless2on Apr 11, 2015 4:10pm

264 Views

Post# 23620042

RE:Has anyone seen a trading alert or anything?

Interesting that this is the first conference in China for rvx and they have been chosen to present, they have announced in previous webcasts about doing regional license deals, now a patent in china for rvx 208, a major recent ru up in share price over the past 6 weeks, this all adds up either a regional license deal or maybe an announcement of starting phase 3......whatever it is things are heating up and getting exciting and still under the radar

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects